Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sarah Batey"'
Autor:
Neil Brewis, Mihriban Tuna, Daniel Gliddon, Sarah Batey, Francisca Wollerton, Sylwia Marshall, Emma Goodman, Robert Hughes, Jose Munoz-Olaya, Raffaella Giambalvo, Alexander Koers, Matthew A. Lakins
All supplementary figures and tables within one powerpoint document
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3070659b0734f48b4b975e2697318a53
https://doi.org/10.1158/1078-0432.22475988
https://doi.org/10.1158/1078-0432.22475988
Autor:
Neil Brewis, Michelle Morrow, Jacqueline Doody, Mihriban Tuna, Lesley Young, Julia Winnewisser, Sarah Batey, Mateusz M. Wydro, Alexander Koers, Claire Seal, Daniel Gliddon, Katarzyna Kmiecik, Natalie L. Allen, Mustapha Faroudi, Matthew Kraman
Kraman et al Supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa847f87a3d220df4360b5b1525c8de6
https://doi.org/10.1158/1078-0432.22478070
https://doi.org/10.1158/1078-0432.22478070
Autor:
Neil Brewis, Michelle Morrow, Jacqueline Doody, Mihriban Tuna, Lesley Young, Julia Winnewisser, Sarah Batey, Mateusz M. Wydro, Alexander Koers, Claire Seal, Daniel Gliddon, Katarzyna Kmiecik, Natalie L. Allen, Mustapha Faroudi, Matthew Kraman
Purpose:Although programmed death-ligand 1 (PD-L1) antibody–based therapy has improved the outcome of patients with cancer, acquired resistance to these treatments limits their clinical efficacy. FS118 is a novel bispecific, tetravalent antibody (m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62277a43acfab114b38aeba6937dccdf
https://doi.org/10.1158/1078-0432.c.6529845.v1
https://doi.org/10.1158/1078-0432.c.6529845.v1
Autor:
Neil Brewis, Mihriban Tuna, Daniel Gliddon, Sarah Batey, Francisca Wollerton, Sylwia Marshall, Emma Goodman, Robert Hughes, Jose Munoz-Olaya, Raffaella Giambalvo, Alexander Koers, Matthew A. Lakins
Purpose:With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer. We have developed FS222, a bispecific tetravalent antibody targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac243270a7bb28aa772748816090a7f
https://doi.org/10.1158/1078-0432.c.6529251
https://doi.org/10.1158/1078-0432.c.6529251
Autor:
Natalie L. Allen, Katarzyna Kmiecik, Daniel Gliddon, Mustapha Faroudi, Julia Winnewisser, Claire Seal, Lesley Young, Neil Brewis, Mihriban Tuna, Matthew Kraman, Sarah Batey, Michelle Morrow, Alexander Koers, Jacqueline Doody, Mateusz Wydro
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(13)
Purpose:Although programmed death-ligand 1 (PD-L1) antibody–based therapy has improved the outcome of patients with cancer, acquired resistance to these treatments limits their clinical efficacy. FS118 is a novel bispecific, tetravalent antibody (m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a06d2dcc4b4284a37ad80bad60c25256
https://pubmed.ncbi.nlm.nih.gov/32299814
https://pubmed.ncbi.nlm.nih.gov/32299814
Autor:
Jose Munoz-Olaya, Sarah Batey, Raffaella Giambalvo, Alexander Koers, Mihriban Tuna, Matthew Lakins, Sylwia Marshall, Neil Brewis, Robert M. Hughes, Francisca Wollerton, Daniel Gliddon, Emma Goodman
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(15)
Purpose: With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer. We have developed FS222, a bispecific tetravalent antibody targ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32090e8cd495982b5484e24855f2f46b
https://pubmed.ncbi.nlm.nih.gov/32345647
https://pubmed.ncbi.nlm.nih.gov/32345647
Autor:
Cristian Gradinaru, Sylwia Marshall, Michelle Morrow, Sarah Batey, Robert M. Hughes, Neil Brewis, Raffaella Giambalvo, Mateusz Wydro, Daniel R. Gliddon, Alexander Koers, Matthew Lakins
Publikováno v:
Cancer Research. 80:4547-4547
Background Activating T cells via clustering tumour necrosis factor receptor superfamily (TNFRSF) has shown promise in cancer therapy. This has typically been achieved by crosslinking of targeting antibodies via Fc-gamma receptor (FcγR). TNFRSF memb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe3076fc822624c692fe62cf3a7f70c7
https://doi.org/10.1158/1538-7445.am2020-4547
https://doi.org/10.1158/1538-7445.am2020-4547
Autor:
Ulrike Von Der Bey, Bernd Schlereth, Julian Bertschinger, Roger Santimaria, Dragan Grabulovski, Susann Koenig-Friedrich, Mathias Locher, Richard Woods, Isabella Attinger-Toller, Michela Silacci, Sarah Batey, Nadja Baenziger-Tobler, Wenjuan Zha, Wibke Lembke
Publikováno v:
mAbs
Biologic treatment options such as tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis. Recent data suggest, however, that full and long-lasting responses to TNF inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db80cb96425eab153bfefa2caa94b9db
https://doi.org/10.1080/19420862.2015.1093266
https://doi.org/10.1080/19420862.2015.1093266
Autor:
Wibke Lembke, Michela Silacci, Julian Bertschinger, Dragan Grabulovski, Nadja Baenziger-Tobler, Wenjuan Zha, Sarah Batey
Publikováno v:
The Journal of Biological Chemistry
Background: IL-17A is a proinflammatory cytokine involved in various inflammatory diseases. Results: Potent IL-17A inhibitors were generated by fusing human Fyn SH3 domain derivatives (Fynomers) to the Fc part of an antibody. Conclusion: The linker l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a74ff35021a81c1740d5197b384c4f9e
https://doi.org/10.1074/jbc.m113.534578
https://doi.org/10.1074/jbc.m113.534578
Autor:
Matthew A. Lakins, Alexander Koers, Jose Munoz Olaya, Raffaella Giambalvo, Daniel Jones, Sarka Pechouckova, Emma Goodman, Sylwia Marshall, Mateusz Wydro, Cristian Gradinaru, Francisca Wollerton, Sarah Batey, Daniel Gliddon, Michael Davies, Michelle Morrow, Mihriban Tuna, Neil Brewis
Publikováno v:
Cancer Research. 79:1540-1540
PD-1/L1 immune checkpoint blockade shows durable responses and extends overall survival in a subset of cancer patients. Tumour Necrosis Factor Receptor (TNFR) activation is being tested clinically to improve patient responses. However, low affinity F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ca01bd12234d73ae8756bd32be0d91c
https://doi.org/10.1158/1538-7445.am2019-1540
https://doi.org/10.1158/1538-7445.am2019-1540